



Special points of interest for Primary Care

- Renal specialist list

SMC advice:

- Iron isomaltoside (Monofer®)
- Quetiapine (Seroquel®), (Seroquel®XL)
- Sunitinib (Sutent®)
- Tadalafil (Adcirca®)
- Ticagrelor (Brilique®)
- Tocofersolan, (Vedrop®)
- Calcium acetate (PhosLo®)



Specialist lists - Renal

The list includes several hospital only medicines and also several medicines which may be prescribed in general practice under specialist direction. These include immunosuppressants for kidney transplant, and phosphate-binding agents. Other medicines that may be prescribed in primary care under specialist direction include calcium polystyrene sulphonate (Calcium Resonium®), oral sodium bicarbonate, oral magnesium glycerophosphate, alfacalcidol and the hepatitis B vaccine (Fendrix®). [CLICK HERE](#) for renal specialist list.

The Chronic Pain, Palliative Care, Rheumatology and Stroke specialist lists are in development.



Prescribing Changes

Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease

NICE technology appraisal guidance 217, March 2011 recommends the following:

- donepezil, galantamine and rivastigmine as options for managing mild and moderate Alzheimer's disease
- memantine as an option for moderate Alzheimer's disease for people who cannot take cholinesterase inhibitors, and as an option for managing severe Alzheimer's disease

NHS Quality Improvement Scotland has advised that these recommendations are valid for Scotland. The NICE recommendation for the use of memantine supersedes earlier SMC not recommended advice issued in January 2004.

The existing NHS Tayside Dementia Shared Care Protocol and Integrated Care Pathway are currently being reviewed to incorporate the above recommendations. Local advice for memantine will be updated once these documents are finalised and local information to support the introduction of memantine has been considered by the Medicines Advisory Group.

Inside this issue :

Specialist lists - Renal	1
Prescribing Changes	1
SMC Advice issued in May 2011	1-2
Updates from previous SMC Advice	2
Drug Safety Updates	2
TAF Updates	3
And Finally.....	4
SMC Briefing Note	4
Forthcoming SMC	4

SMC Advice issued in May 2011

SMC website: www.scottishmedicines.org.uk

Medicine	Indication	Local recommendation category	Comments and useful links
Iron isomaltoside 1000, 100mg/mL solution for injection/infusion (Monofer®) (697/11) - Full submission	Treatment of iron deficiency anaemia in the following conditions: - when oral iron preparations are in-effective or cannot be used; - where there is a clinical need to deliver iron rapidly.	Pending* specialist feedback	SMC advice

Medicine	Indication	Local recommendation category	Comments and useful links
Quetiapine, 25mg, 100mg, 150mg, 200mg, 300mg tablets (Seroquel®), quetiapine, 50mg, 150mg, 200mg, 300mg, 400mg sustained release tablets (Seroquel®XL) (549/09) - Re-submission	Treatment of major depressive episodes in bipolar disorder.	Not recommended	SMC advice
Sunitinib 12.5mg, 25mg, 37.5mg, 50mg hard capsules (Sutent®) (698/11) - Full submission	Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults.	Pending* OHMMG decision	SMC advice
Tadalafil 20 mg film-coated tablets (Adcirca®) (710/11) - Non-submission	For the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity.	Not recommended	SMC advice
Ticagrelor 90mg film-coated tablets (Brilique®) (699/11) - Full submission	Co-administered with aspirin, for the prevention of atherothrombotic events in adult patients with acute coronary syndromes; including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).	Pending* specialist feedback	SMC advice
Tocofersolan, 50mg/mL, oral solution (Vedrop®) (696/11) - Full submission	Vitamin E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region.	Not recommended	SMC advice

* 'pending' means that no local recommendation to support use is in place at the current time

OHMMG - Oncology and Haematology Medicines Management Group

Updates from previous SMC Advice

Medicine	Indication	Local recommendation category	Comments and useful links
Calcium acetate 667mg hard capsules (PhosLo®) - Abbreviated submission	Prevention/treatment of hyperphosphataemia in patients with advanced renal failure on dialysis.	GPs may prescribe under the direction of the Renal Clinic Formulary - Renal Specialist list	SMC advice SPC link



Drug Safety Updates

Please follow link -

[Drug Safety Update, Volume 4, Issue 10, May 2011](#)



Tayside Area Formulary (TAF) Updates - May/June 2011

TAF Section	Drug(s)/topic	Changes
Specialist formulary lists and formulary development		Link to Renal specialist list added. CLICK HERE
Appendices—Specialist formulary lists	Renal	Renal specialist list added.
8.1	Cyclophosphamide	New section 8.1 created with cyclophosphamide (hospital only) added to formulary and Renal specialist list for use in accordance with cyclophosphamide protocol .
8.2	Drugs affecting the immune response	New section 8.2 created with mycophenolate mofetil, tacrolimus (Prograf®/Advagraf®), azathioprine, ciclosporin (Neoral®/Sandimmun®) and sirolimus (Rapamune®) added to formulary and Renal specialist list for immunosuppression in kidney transplant.
9.1	Parenteral iron	Iron sucrose (Venofer®) (hospital only) added to formulary and Renal specialist list.
	Drugs used in renal anaemia	Darbepoetin alfa (Aranesp®) (first choice erythropoiesis stimulating agent), epoetin beta (NeoRecormon®), and methoxy polyethylene glycol-epoetin beta (Micera®) (all hospital only) added to formulary and Renal specialist list for renal anaemia.
9.2	Potassium removal	Calcium polystyrene sulphonate (Calcium Resonium®) added to formulary and Renal specialist list for use in accordance with Management of Hyperkalaemia in Dialysis Patients on the Acute Medical Unit (AMU) guidance (NHS Tayside Staffnet intranet link only) or Management of Acute Hyperkalaemia on AMU in patients NOT Receiving Regular Dialysis (NHS Tayside Staffnet intranet link only).
	Oral bicarbonate	Sodium bicarbonate 500mg capsules added to formulary and Renal specialist list.
9.5	Phosphate-binding agents	Calcium acetate (Phosex®) (first choice phosphate - binding agent), calcium acetate (PhosLo®), and calcium carbonate (Calcichew®) added to formulary and Renal specialist list. Sevelamer hydrochloride (Renagel®) and sevelamer carbonate (Renvela®) added to formulary and Renal specialist list for hyperphosphataemia in Chronic Kidney Disease (CKD) in patients unable to take calcium based phosphate binders. Lanthanum (Fosrenol®) added to formulary and Renal specialist list for patients intolerant to sevelamer.
	Secondary hyperparathyroidism	Cinacalcet (Mimpara®) (hospital only) added to formulary and Renal specialist list for severe refractory secondary hyperparathyroidism in patients with End-Stage Renal Disease (ESRD) in whom parathyroidectomy is contraindicated.
	Hypomagnesaemia	Magnesium glycerophosphate (unlicensed) 500mg capsules, from Martindale (containing approximately 2 mmol of magnesium per capsule) added to formulary and Renal specialist list.
9.6	Vitamin D	Alfacalcidol added to formulary and Renal specialist list for vitamin D deficiency and/or secondary hyperparathyroidism.
14 - Alert antibiotics and Antibiotic drug dosages	Valganciclovir *	Addition of information on extended duration of prophylaxis of cytomegalovirus (CMV) in kidney transplant patients to 200 days post-transplantation.
16	Immunisations	Hepatitis B vaccine (Fendrix®) added to Renal specialist list for immunisation against hepatitis B infection in patients with CKD including those on haemodialysis. Addition of link to NHS Tayside Immunisation policy (NHS Tayside Staffnet intranet link only) for guidance on administration of immunisations/vaccinations to Immunisations sub-section within section 16.

* SMC accepted medicine

And Finally.....

SMC Briefing Note:

[Click here](#) for May Briefing Note

[Forthcoming SMC Advice](#)

This bulletin is produced by the Medicines Advisory Group (MAG), which is a sub-group of the NHS Tayside Drug and Therapeutics Committee.

Please direct any queries to either:

Karen Harkness
Principal Pharmacist - Clinical Effectiveness
email: kharkness@nhs.net

or

Claire James
Senior Pharmacist - Clinical Effectiveness
email: clairejames@nhs.net

Local implementation of SMC recommendations is taken forward by the Tayside Medicines Governance Unit. This bulletin is based on evidence available to the Tayside Medicines Governance Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use.

[CLICK HERE](#) for access to the Medicines Governance section of the Pharmacy Staffnet site.